CORONAVIRUS

Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine

Christopher L. D. McMillan^{1†}, Jovin J. Y. Choo^{1†}, Adi Idris², Aroon Supramaniam², Naphak Modhiran¹, Alberto A. Amarilla¹, Ariel Isaacs¹, Stacey T. M. Cheung¹, Benjamin Liang¹, Helle Bielefeldt-Ohmann^{1,3,4}, Armira Azuar¹, Dhruva Acharya², Gabrielle Kelly², Germain J. P. Fernando^{1,5}, Michael J. Landsberg^{1,3}, Alexander A. Khromykh^{1,3}, Daniel Watterson^{1,3}, Paul R. Young^{1,3}, Nigel A. J. McMillan², David A. Muller^{1*}

Copyright © 2021
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim to
original U.S. Government
Works. Distributed
under a Creative
Commons Attribution
License 4.0 (CC BY).

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 160 million people and resulted in more than 3.3 million deaths, and despite the availability of multiple vaccines, the world still faces many challenges with their rollout. Here, we use the high-density microarray patch (HD-MAP) to deliver a SARS-CoV-2 spike subunit vaccine directly to the skin. We show that the vaccine is thermostable on the patches, with patch delivery enhancing both cellular and antibody immune responses. Elicited antibodies potently neutralize clinically relevant isolates including the Alpha and Beta variants. Last, a single dose of HD-MAP–delivered spike provided complete protection from a lethal virus challenge in an ACE2-transgenic mouse model. Collectively, these data show that HD-MAP delivery of a SARS-CoV-2 vaccine was superior to traditional needle-and-syringe vaccination and may be a significant addition to the ongoing COVID-19 (coronavirus disease 2019) pandemic.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus that emerged in 2019 in Wuhan, China (1), before rapidly spreading around the globe causing the coronavirus disease 2019 (COVID-19) pandemic. As of 11 August 2021, SARS-CoV-2 has caused more than 202 million infections resulting in more than 4.2 million deaths (<https://covid19.who.int>). The rapid spread of SARS-CoV-2 was accompanied by the rapid development of multiple vaccines. Many vaccine modalities were trialed including mRNA (2–4), DNA (5), protein subunit (6, 7), viral vectored (8–11), nanoparticle (12), and inactivated virus (13, 14), and several have subsequently been granted emergency authorization for use in humans. However, the emergence of SARS-CoV-2 variants of concern that have varying degrees of resistance to neutralization by sera from vaccinated individuals is raising concerns of vaccine escape, highlighting the need for further vaccine research and development (15–18). Furthermore, some of these vaccines require ultralow-temperature storage and show only limited stability at 2° to 8°C (19), making transport and global distribution challenging, especially to resource-limited countries. Meeting the demand of vaccine doses for global vaccination coverage in a pandemic has also proven problematic, and dose-sparing methods could prove useful.

One such approach to improving vaccine stability, dose-sparing, and ease of distribution is the high-density microarray patch (HD-MAP). The HD-MAP is a 1 × 1 cm solid polymer microprojection array

containing 5000 projections of 250 μm in length (20). Vaccine is coated onto the microprojections via a nitrogen jet–based drying process (20) before application to the skin at a velocity of 18 to 20 m/s via a spring-loaded applicator. This delivers the vaccine directly to the epidermal and upper dermal layers of the skin, which are rich in antigen-presenting cells (21–23). This vaccine modality offers considerable advantages in thermostability and antigenicity (20, 24, 25) with dose-sparing of a large range of vaccines previously observed (26–33). In addition, HD-MAP application avoids the generation of sharps waste and offers advantages in terms of ease of application, potentially negating the need for highly trained health-care workers (34, 35).

Here, we explore HD-MAP delivery of a subunit vaccine candidate—a recombinant SARS-CoV-2 spike glycoprotein, termed HexaPro, which has been stabilized in its prefusion conformation by removal of the furin cleavage site and the inclusion of six stabilizing proline mutations (36). We found that immunization of mice with spike via HD-MAP application induced significantly higher antibody levels than intradermal needle-and-syringe (N&S) delivery, with neutralization of virus observed after just one dose. In addition, immunization of transgenic mice expressing human angiotensin-converting enzyme 2 (ACE2) with spike protein via HD-MAP delivery and adjuvanted with QS21 provided complete protection from a lethal SARS-CoV-2 challenge after only one dose, with no virus replication observed in the lungs or brain of the mice.

RESULTS

SARS-CoV-2 spike (HexaPro) expression and formulation development

HexaPro (36), a stabilized SARS-CoV-2 spike protein containing six proline substitutions and a mutated furin cleavage site (hereafter referred to as spike) was recombinantly expressed using the Expi293-F expression system and purified via immunoaffinity chromatography. After initial in vitro characterization to confirm integrity and conformational folding of the protein (fig. S1), we

¹School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland 4072, Australia. ²Menzies Health Institute Queensland, School of Pharmacy, Anatomy and Medical Sciences, Griffith University, Gold Coast, Queensland 4222, Australia. ³Australian Infectious Diseases Research Centre, Global Virus Network Centre of Excellence, Brisbane, Queensland 4072 and 4029, Australia. ⁴School of Veterinary Science, University of Queensland Gatton Campus, Gatton, Queensland 4343, Australia. ⁵Vaxxas Pty Ltd, Translational Research Institute, 37 Kent Street, Brisbane, Queensland 4102, Australia.

*Corresponding author. Email: d.muller4@uq.edu.au

†These authors contributed equally to this work.

Fig. 1. Spike vaccine and the HD-MAP. (A) The HD-MAP relative and 27-gauge needle. (B) Temperature stability of dry-coated spike protein with various concentrations of human serum albumin (HSA) after 7 days at the indicated temperatures (C) or with 0.25% HSA for the indicated temperatures and time. Data presented as mean with error bars representing SEM. (D) Scanning electron microscope (SEM) images of HD-MAPs either uncoated or coated with spike vaccine formulations, before and after delivery into the skin of mice. White arrowheads indicate levels of vaccine removal post-delivery. (E) Delivery efficiency into the skin of mice of spike and spike + QS21-coated HD-MAPs. (F) HD-MAP delivery site on the flank of a mouse immediately after HD-MAP application and removal.

investigated formulation and coating optimization on the HD-MAP (Fig. 1A). Initial experiments focused on the selection of generally regarded as safe excipients that stabilize the protein in both the dry-down process and storage over time. Excipients tested included sugars, proteins, and denaturing agents, which have previously been shown to stabilize vaccines on the HD-MAP (28, 30). Stability was assessed by enzyme-linked immunosorbent assay (ELISA), through the binding of a conformational-dependent, spike-reactive monoclonal antibody (mAb) S309 (37). While minimal reduction in antigenicity was observed during the dry-down process (measured following immediate reconstitution), storage for 1 or 7 days at 4°C resulted in considerable loss of antigenic reactivity for some excipients (fig. S2). However, all formulations containing human serum albumin (HSA) resulted in antigenic stability at all time points.

Next, we investigated the stability of spike-HSA formulations at elevated temperatures and to further optimize the concentration of HSA required to confer stability. To achieve this, spike was dried with or without HSA [0.25 to 0.75% (w/v)] and stored at 25° or 40°C and assessed for antigenic stability by ELISA as before. The losses upon storage at both 25° and 40°C ranged between 1 and 13% after 1 week when HSA was included in the formulation, with higher losses in antigenic integrity of more than 20% at 40°C observed with spike alone (Fig. 1B). Given the minimal differences in stabilization afforded by all HSA concentrations tested, we chose to proceed with the lowest effective concentration of 0.25% for future formulations to minimize the solid mass required to be dried down on the patch projections. The effects of storage over an extended time period was

also assessed. After 1 month at 25°C in the presence of 0.25% HSA, full antigenic reactivity was recovered, suggesting excellent stability (Fig. 1C). While 1 week of storage at 40°C resulted in minimal antigenic loss, 1 month storage at this elevated temperature resulted in limited antigenic recovery (Fig. 1C). As the addition of HSA greatly improved antigenic stability at all temperatures tested, HSA at 0.25% was included in all subsequent HD-MAP vaccine formulations.

We next assessed the delivery efficiency of the vaccine from the coated HD-MAP to mouse skin. When applying spike-coated HD-MAPs to the skin of mice, removal of the vaccine coating can be observed by scanning electron microscopy (SEM) of the patches before and after delivery (Fig. 1D). We also included the saponin-based adjuvant QS21, based on previous data demonstrating its potent adjuvanting effects and compatibility for coating onto the HD-MAP (30, 38). Efficient removal of vaccines containing QS21 into the skin of mice was also observed. This vaccine removal corresponded to an average delivery of 50 to 60% of the payload as assessed via ELISA of spike able to be eluted off the patch after application (Fig. 1E) and was accompanied by visual signs (erythema and petechiae) of HD-MAP engagement with the depilated skin in all animals (Fig. 1F). Complete resolution was observed within 3 to 5 days, consistent with previous studies (23, 39).

Immunogenicity of HD-MAP-delivered spike

We next sought to assess the immunogenicity of SARS-CoV-2 spike delivered with or without adjuvant, and either via HD-MAP application

or intradermal injection using N&S. We chose intradermal injection, rather than traditional intramuscular vaccination, as it is a more relevant comparator to HD-MAP delivery of vaccines to the immune cell-rich environment of the skin. BALB/c mice were immunized twice at 21-day intervals with 2 μ g of spike alone or with the addition of QS21 (Fig. 2A). HD-MAPs coated with excipients only were included as controls. Blood was collected 20 days after each immunization and the serum was assessed for spike-specific immunoglobulin G (IgG) by ELISA. After one immunization, both nonadjuvanted and QS21-adjuvanted spike delivered by HD-MAP induced significantly higher ($P < 0.0001$) IgG levels compared to their intradermally delivered controls (Fig. 2B). This trend was mirrored in the response after two doses, with levels approximately 40-fold higher after a second immunization in both HD-MAP groups. Promisingly, serum from the nonadjuvanted HD-MAP spike group had significantly higher ($P < 0.0001$) IgG titers compared to QS21-adjuvanted intradermally delivered spike, highlighting the immune-enhancing attributes of the HD-MAP alone. Serum from day 41 also contained high levels of IgG able to bind to the receptor-binding domain (RBD) and N-terminal domain (NTD) of the spike protein (fig. S3), indicating broad coverage of epitopes known to be bound by neutralizing antibodies (nAb) (37, 40–42). Again, IgG levels were higher in HD-MAP-immunized animals compared to

their intradermally injected counterparts. This was especially apparent for NTD-specific IgG levels, where complete seroconversion in both nonadjuvanted and adjuvanted groups was observed in HD-MAP groups compared to only partial seroconversion for intradermally injected spike (0% for nonadjuvanted and 62.5% for adjuvanted).

To investigate the functionality of the induced immune response, we assessed the serum for its ability to neutralize SARS-CoV-2 virus via plaque-reduction neutralization test (PRNT) against an early SARS-CoV-2 isolate, QLD02, matching closely to the original Wuhan-Hu-1 strain. Following one dose, HD-MAP-spike-immunized mice had detectable levels of nAbs in the serum, which were boosted ~50-fold after a second immunization (Fig. 2C). Conversely, spike intradermally immunized mice had no detectable nAbs after one dose. Although the second intradermal immunization induced a nAb response in mice receiving spike adjuvanted with QS21, this response was significantly lower than their HD-MAP counterparts ($P < 0.0001$; Fig. 2C). Furthermore, with no adjuvant and after two doses, intradermally delivered spike induced a nAb response in only a subset (62.5%) of animals.

An important site of immunity for respiratory infections such as SARS-CoV-2 is at mucosal surfaces (43) of the respiratory tract, and an ideal vaccine would induce immunity at these surfaces. To assess

Fig. 2. Immunogenicity of HD-MAP spike vaccination in mice. (A) Vaccination and bleed schedule of BALB/c mice ($n = 7$ or 8 per group) immunized with spike vaccine via HD-MAP application or intradermal (i.d.) delivery. Serum was collected on day 20 or 42 and analyzed for (B) IgG titer by ELISA and (C) virus neutralization by plaque reduction neutralization test (PRNT) against the SARS-CoV-2 virus hCoV-19/Australia/QLD02/2020 (GISAID accession ID EPI_ISL_407896). Bronchoalveolar lavage (BAL) was collected on day 42 and analyzed for (D) IgG titers as measured by ELISA and (E) virus neutralization by PRNT. (F) Interferon- γ (IFN- γ) enzyme-linked immunosorbent assay (ELISpot) of splenocytes collected on day 42. Data representative of geometric mean with error bars representing SD. P values indicate results of one-way ANOVA with Tukey's multiple comparison post hoc test.

antibody levels at mucosal surfaces, we performed bronchoalveolar lavage (BAL) at the lungs of mice and analyzed antibody levels via ELISA and PRNT. Similar to trends observed in serum IgG analysis, mice receiving spike via HD-MAP induced significantly higher IgG titers compared with their intradermal counterparts ($P < 0.0001$ for both adjuvanted and nonadjuvanted groups; Fig. 2D). Furthermore, all HD-MAP-immunized mice produced virus-neutralizing responses, with the inclusion of QS21 boosting this response (Fig. 2E). For intradermally delivered spike alone, BAL neutralization activity was detected in only one animal. The inclusion of QS21 for intradermal delivery resulted in improved BAL neutralization activity, with 62.5% of mice producing a neutralizing response (Fig. 2E).

Cellular immunity to SARS-CoV-2 is an important component of patient recovery from COVID-19 and in providing protection from viral variants (44–46). To provide an indicative measure of the cellular response induced by immunization with HD-MAP delivered spike, spleens from mice were harvested at day 42 and splenocytes were assessed via interferon- γ (IFN- γ) enzyme-linked immunospot (ELISpot). Delivery of spike + QS21 by HD-MAP induced an average of 290 spot-forming units (SFU) per 10^6 splenocytes, which was significantly higher compared to intradermal delivery of the same formulation ($P < 0.0001$, Fig. 2F). With no adjuvant, an average of 65 SFU per 10^6 splenocytes was observed when delivered via HD-MAP, compared to only 6 for intradermal delivery. This is a good initial indication that cellular immunity is induced by

HD-MAP immunization, which complements the high IgG titers in the serum and at mucosal sites.

Serum was further analyzed for neutralization of SARS-CoV-2 variants of concern that have recently emerged (15–18). These variants, which included an isolate containing the D614G mutation in the spike protein (47), an Alpha variant (lineage B.1.1.7), and a Beta variant (lineage B.1.351), have been shown to have a functional phenotype characterized by increased ACE2 binding affinity, increased transmissibility, and escape from nAb binding (15–18, 47, 48). Promisingly, nAb levels in day 42 serum from HD-MAP-immunized mice showed no significant decrease in neutralizing activity when tested against any of these variants, although there was a trend for decreased responses against the Beta isolate (Fig. 3 and fig. S4). When spike was delivered via the intradermal route, significant decreases in nAb activity ($P = 0.0159$) were observed against the Beta virus, although all samples were still neutralizing (Fig. 3B).

Protection in mice after a single dose of HD-MAP-delivered spike

With the observation that HD-MAP immunization induced significantly higher IgG and cellular immune responses relative to N&S intradermal delivery, we next assessed HD-MAP vaccine potency in a SARS-CoV-2 challenge model. Transgenic mice expressing human ACE2 driven by the cytokeratin-18 (K18) promoter (K18-hACE2 mice) have been shown to be an effective model for SARS-CoV-2 infection (49) and were used in this study. Mice ($n = 8$) were immunized

Fig. 3. Serum neutralization against SARS-CoV-2 viral variants. Serum from mice ($n = 7$ or 8 per group) was collected 21 days after the second immunization with SARS-CoV-2 spike with or without the adjuvant QS21, either via intradermal injection (A and B) or HD-MAP application (C and D). ns, not significant. Serum was tested for neutralization against an isolate containing the 614G mutation (hCoV-19/Australia/QLDID935/2020, GISAID accession ID EPI_ISL_436097), an Alpha variant (from the lineage B.1.1.7) (hCoV-19/Australia/QLD1517/2021, GISAID accession ID EPI_ISL_944644), and a Beta variant (from the lineage B.1.351) (hCoV-19/Australia/QLD1520/2020, GISAID accession ID EPI_ISL_968081), and PRNT50 values were compared to the parental strain containing the 614D in the spike protein (hCoV-19/Australia/QLD02/2020, GISAID accession ID EPI_ISL_407896). Data represent geometric mean of individual mice and P values represent results of a paired two-tailed t test. Dotted lines show assay limit of detection.

via HD-MAP with either a single dose or a prime/boost regime at 21-day intervals, with or without QS21 as an adjuvant, or left unimmunized as naïve controls (Fig. 4A). Blood was taken for analysis of serum IgG levels via ELISA and PRNT before challenge, which occurred 21 days after the final immunization. At this time, all immunized mice had seroconverted with high levels of spike-specific IgG, and all had high levels of nAbs against the 614D, 614G, and Alpha virus isolates, although nAb levels against the Beta isolate were lower (Fig. 4B and fig. S5). Mice were then challenged with 10^4 PFU of an early isolate of SARS-CoV-2 [hCoV-19/Australia/VIC01/2020, Global Initiative on Sharing all Influenza Data (GISAID) accession ID EPI_ISL_406844, matching to the Wuhan-1 reference virus (50)] via intranasal inoculation and monitored daily for weight loss and clinical signs of infection. By day 5 after infection, all naïve mice were showing clinical signs of infection, and subsequently

required euthanasia by day 6 due to weight loss and clinical scores (Fig. 4, C to E). Of those mice receiving a single dose of non-adjuvanted spike, four of eight also showed clinical signs of infection and required euthanasia at day 6. All other immunized mice had no observable signs of clinical infection or weight loss at this time. To compare viral loads and histopathology of tissue at the peak of infection, four of eight animals from all other groups were also euthanized. The remaining mice were then monitored daily until day 14 after infection. Both the lungs and brains of naïve mice showed high levels of virus at day 6 after infection (log-transformed mean titers of 4.2 PFU/g in the lungs and 8.8 PFU/g in the brains) (Fig. 4, F and G), consistent with previous reports of SARS-CoV-2 infection in K18-hACE2 mice (49, 51). The mice receiving a single dose of nonadjuvanted spike had detectable virus levels in the brain (log-transformed titer of 6.8 PFU/g), albeit at significantly lower

Fig. 4. HD-MAP vaccination of K18-hACE2 mice and protection from virus challenge. (A) Immunization and challenge schedule for K18-hACE2 mice ($n = 8$ per group) vaccinated with HD-MAP spike (single dose or prime/boost regime) and challenge with SARS-CoV-2 (hCoV-19/Australia/VIC01/2020, GISAID accession ID EPI_ISL_406844). (B) Neutralization titers of serum collected before challenge (day 20 or 41 for single dose and prime/boost, respectively) against hCoV-19/Australia/QLD02/2020. (C to E) Body weight, survival, and clinical score of mice throughout the course of the challenge. Viral titer in the (F) lungs and (G) brain of mice at day 6 after infection. P values for survival curve represent results of the log-rank test relative to naïve mice with a K value of 4 and a Bonferroni threshold of 0.0125. P values for body weight and clinical score graphs represent results of repeated-measures one-way ANOVA relative to naïve mice with Dunnett's test for multiple comparisons. All other graphs have data representing geometric mean with error bars representing geometric SD and P values indicating results of one-way ANOVA with Tukey's multiple comparison post hoc test.

levels ($P = 0.0005$) than naïve mice but no detectable virus in the lungs (Fig. 4, F and G). These mice had however been euthanized because of signs of infection. Mice in this group that did not show symptoms were not analyzed at this time point. Conversely, all other immunization regimes (a single dose of QS21-adjuvanted spike, two doses of adjuvanted spike, and two doses of nonadjuvanted spike) completely inhibited infection as evidenced by no detectable virus in the lungs at day 6 after infection (Fig. 4, F and G). Histopathological analysis of lung and brain tissue revealed mild-to-moderate perivascular and interstitial leukocyte infiltration in the lungs of naïve and single-dose immunized mice (fig. S6A). This was reduced in mice receiving two doses of vaccine. Similar trends were observed in brain tissue, with perivascular cuffing, neutrophil infiltration, neural degeneration, and gliosis observed in naïve and single-dose mice, with mice from two dose groups appearing normal (fig. S6B).

DISCUSSION

Here, we report the combination of a SARS-CoV-2 spike subunit protein vaccine candidate with the HD-MAP vaccine delivery platform, resulting in a stable and effective vaccine candidate against SARS-CoV-2. With the HD-MAP platform, dry-coated vaccine is delivered directly to the immune-rich epidermis and upper dermal layers of the skin, while simultaneously causing localized cell death and inflammation, both of which serve to enhance vaccine-induced immunity (22, 52). This platform delivery system offers a number of other benefits, including ease of administration, and potentially self-administration or administration by individuals who are not trained health care professionals, reduced cold chain dependence, no requirement for reconstitution, and improved thermostability. We showed that the dry-coated spike protein was thermostable (as measured by conformational epitope integrity), with stability observed for up to a month at 25°C and a week at 40°C (Fig. 1, B and C). Others investigating the temperature sensitivity of the spike protein (albeit in liquid formulations and without the additional stabilizing mutations found in HexaPro) found that storage at 22°C for 5 to 7 days resulted in substantial (>40%) losses in structural integrity (53). Another recombinant spike vaccine candidate showed similar changes at these temperatures (7). Should this antigenic measure of stability translate to overall structural stability, this represents a marked improvement over other SARS-CoV-2 vaccine candidates, especially mRNA vaccines, where limited stability (2 to 24 hours) at room temperature is observed (19). This lends itself well to improvements in vaccine transport and delivery to patients, especially in a “last-mile” context where appropriate infrastructure may be limited. This is particularly relevant to low-to-middle-income countries, where there is an urgent need to facilitate vaccination of populations against SARS-CoV-2 (54, 55).

HD-MAP-delivered spike resulted in a robust neutralizing IgG and cellular immune response in mice, which was superior to delivery of the same vaccine via intradermal N&S immunization. This is consistent with previous studies using the HD-MAP where significant improvements in immunogenicity were observed (22, 25, 28, 30, 31, 56). As previously reported, the enhanced immune response observed with HD-MAP application is due to the colocalization of vaccine with localized cell death caused by mechanical stresses (22). This induces tumor necrosis factor and nuclear factor κ B signaling pathways, contributing to enhanced vaccine-induced adaptive

immune responses. The inclusion of QS21, which is known to broaden the immune response and enhance cell-mediated immunity (38), induced high levels of spike-specific IFN- γ -secreting T cells and increased the magnitude of RBD- and NTD-specific antibodies, although this did not reach statistical significance compared to nonadjuvanted HD-MAP spike. The broad IgG response observed resulted in neutralization of representative emerging viral variants, including an isolate containing the 614G mutation in the spike protein and Alpha and Beta variants. These variants, which appear to have supplanted the ancestral virus, have shown escape from neutralization by some monoclonal nAbs and vaccine-induced serum (15–18, 47, 48). These collective findings are promising given the importance of cellular immunity in protection from severe SARS-CoV-2 disease (45, 46, 57). In addition, the HD-MAP appears to provide improved immunogenicity and cellular responses to SARS-CoV-2 vaccine candidates when compared to immunization with other lower-density MAP delivery systems (58, 59). Together, these data suggest that HD-MAP vaccination could provide improved cellular immune responses and an increased magnitude of IgG response, both of which would limit the potential for escape from protection by emerging viral variants.

Immunization of K18-hACE2 mice with spike via HD-MAP resulted in complete protection from disease after just a single QS21-adjuvanted dose. The protective immune response resulted in abrogation of virus replication in both the lungs and brain tissue assessed on day 6 after infection, in contrast to naïve mice, which had high levels of replicating virus in these organs (Fig. 4, F and G). This is notable as SARS-CoV-2 infection has been shown to infect the brain of humans and mice, causing meningitis and encephalitis (51, 60, 61). While caution should be taken extrapolating animal data to potential human efficacy, protection with a single dose would provide significant benefits for rollout of mass vaccination campaigns during a pandemic. Only requiring a single dose to achieve protection would mean fewer doses to be manufactured and more rapid vaccine coverage of populations, in contrast to most current SARS-CoV-2 vaccines that require two doses 3 to 12 weeks apart to achieve protection (62–65). Although some adenovirus-vectored vaccines have been shown to provide single-dose protection from SARS-CoV-2 infection in mice and humans (66, 67), issues surrounding safety and extremely rare undesired adverse events have affected their clinical rollout (68). Subunit vaccines therefore offer an improved and more desirable safety profile without these undesired events.

To date, only limited studies investigating subunit-based SARS-CoV-2 vaccines have been performed, and while single-dose protection has been observed, this was achieved with much higher doses than the 2 μ g used here. Tian *et al.* (6) used 10 μ g of a full-length spike protein vaccine with Matrix-M adjuvant and saw protection after a single dose, although signs of infection were still observed in mice. Without Matrix-M, the same 10- μ g dose offered little protection even after two doses. Another study used a spike nanoparticle vaccine in which multiple spike proteins are assembled on a nanoparticle (69). Immunization provided protection in hamsters, although this immunity was not complete and required a dose of 100 μ g, 50 times higher than required by HD-MAP immunization (69). Other work using a prefusion-stabilized spike protein (5 μ g/dose, adjuvanted with MF59) showed reduced viral load in the lungs and throat swabs of hamsters on day 4 after infection after one or two immunizations (7), with relatively high levels of replicating

virus still recovered from these samples. In addition, neither regime decreased the viral load in the nasal turbinates compared to naïve hamsters on day 4 or day 8 after infection (7). This suggests that the antibody and/or cellular immunity induced by these vaccination regimes were not high enough to inhibit viral replication in these organs.

In conclusion, this body of work demonstrates the first investigation of SARS-CoV-2 spike vaccination via a MAP. HD-MAP spike vaccines are stable, immunogenic, and protective against virus challenge in mice after a single dose. These findings represent a substantial improvement in many areas of SARS-CoV-2 vaccination and offer a promising alternative to currently available vaccines that warrants further investigation in the context of human SARS-CoV-2 infection.

MATERIALS AND METHODS

Animal ethics and animals

Female BALB/c and K18-hACE2 transgenic mice were purchased from the Animal Resources Centre (Perth, Australia) and housed in pathogen-free conditions at the Australian Institute for Bioengineering and Nanotechnology or Griffith University. All animal procedures were approved by the University of Queensland and Griffith University animal ethics committees (approval numbers: SCMB/322/19/AIBN and MHIQ/12/20/AEC).

Cell lines

Expi293-F and ExpiCHO-S cells were purchased from Thermo Fisher Scientific and maintained as per the manufacturer's instructions. VeroE6 cells were purchased from the American Type Culture Collection (ATCC) (catalog, ATCC CRL-1586) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Bovogen, USA), penicillin (100 U/ml), and streptomycin (100 µg/ml) at 37°C with 5% CO₂.

Viruses

Low-passage virus isolates of SARS-CoV-2 that were recovered from nasopharyngeal aspirates of infected individuals were provided by the Queensland Health Forensic and Scientific Services, Queensland Department of Health, Peter Doherty Institute for Infection and Immunity and Melbourne Health, Victoria, Australia. Virus isolates used in this study include the early Australian isolates hCoV-19/Australia/QLD02/2020 (GISAID accession ID, EPI_ISL_407896, collected on 30 January 2020) and hCoV-19/Australia/VIC01/2020 (50) (GISAID accession ID EPI_ISL_406844, collected on 25 January 2020), an isolate containing the D614G mutation (hCoV-19/Australia/QLDID935/2020, GISAID accession ID EPI_ISL_436097, collected on 25 March 2020), an isolate of the B.1.1.7 lineage, now referred to as the Alpha variant (hCoV-19/Australia/QLD1517/2021, GISAID accession ID EPI_ISL_944644, collected on 6 January 2021), and an isolate of the B.1.351 lineage, now referred to as the Beta variant (hCoV-19/Australia/QLD1520/2020, GISAID accession ID EPI_ISL_968081, collected on 29 December 2020). Virus isolates were further propagated on VeroE6 cells and stocks stored at −80°C. Virus titer was determined by immunoplaque assay as previously described (70).

Plasmids

The plasmid encoding SARS-CoV-2 S HexaPro was a gift from J. McLellan (Addgene plasmid no. 154754; <http://n2t.net/addgene:154754>;

RRID, Addgene_154754). However, this construct that encodes the spike protein from the prototype Wuhan-Hu-1 SARS-CoV-2 virus isolate has been modified to include a cleavage site substitution, as well as six prolines for stability (36). Plasmids encoding heavy and light chains of SARS-CoV-2 S-specific antibodies and spike RBD and NTD constructs were constructed in-house as previously described (7, 70, 71).

Recombinant antibody expression and purification

Plasmids encoding the heavy and light chains of mAbs were prepared using the PureYield Plasmid Midi- or Maxi-prep system and filter sterilized using a 0.22-µm filter. Plasmids were then transfected into ExpiCHO-S cells (Thermo Fisher Scientific) as per the manufacturer's instructions. Culture supernatant was harvested via centrifugation at 7 days after transfection and antibodies were purified using Protein A affinity chromatography on an AKTA pure FPLC system (Cytiva) as per the manufacturer's instructions. Purified antibodies were concentrated and buffer-exchanged into phosphate-buffered saline (PBS) using a 30-kDa molecular weight cutoff Amicon Ultra Centrifugal Filter (Merk) and stored at −20°C until use.

Fc-fusion protein expression and purification

Plasmids containing the RBD and NTD of SARS-CoV-2 spike fused to human Fc were prepared using the PureYield Plasmid Midi- or Maxi-prep system and filter-sterilized using a 0.22-µm filter. Plasmids were then transfected into ExpiCHO-S cells (Thermo Fisher Scientific) as per the manufacturer's instructions. Culture supernatant was harvested and protein was purified via Protein A affinity chromatography as before.

SARS-CoV-2 spike HexaPro expression and purification

Plasmid DNA for transfection was prepared using Promega PureYield Plasmid Maxiprep System and filter-sterilized using a 0.22-µm filter before transfection into Expi293-F cells (Thermo Fisher Scientific), as per the manufacturer's instructions. Culture supernatant was clarified by centrifugation at 5000g for 30 min at 4°C before filtration through a 0.22-µm filter. Protein was purified from supernatants as previously described (7), using an in-house made immunoaffinity purification column containing the S-specific mAb 2M-10B11. After purification, proteins were concentrated and buffer-exchanged into PBS as before, and stored at −20°C. Protein was assessed for purity SDS-polyacrylamide gel electrophoresis using a 4 to 12% NuPage SDS gel and size exclusion chromatography using a Superdex 200 Increase 10/300 GL column. Purified spike protein was also analyzed via ELISA. Briefly, SARS-CoV-2 S protein was coated onto ELISA plates at 2 µg/ml in PBS and incubated at 4°C overnight. The next day, plates were blocked with 5% milk diluent blocking concentrate (Seracare) for 30 min at room temperature. Serial dilutions of antibodies were then added to the plates before incubation at 37°C for 1 hour. After washing with PBS with 0.05% Tween 20, relevant horseradish peroxidase (HRP)-conjugated secondary antibodies were added (goat anti-mouse or anti-human, diluted 1:2000). After washing, 3,3',5,5'-tetramethylbenzidine (TMB) substrate was then added to develop the ELISA before stopping the reaction with 1 M phosphoric acid. Absorbance was then read at 450 nm using a Varioskan LUX Microplate reader (Thermo Fisher Scientific).

Stability dry-down assay

Spike protein was formulated as desired and added to wells of a 96-well tissue culture plate before being placed under a filtered

nitrogen gas jet stream at 15 liter/min for 15 min using a MICROVAP microplate evaporator (PM Separations). Plates were then sealed in foil bags containing desiccant and stored for the desired time. To reconstitute, 150 μ l of 5% milk diluent blocking concentrate (Seracare) diluted in PBS containing 0.05% Tween 20 was added to each well. Reconstitution was achieved by pipetting and incubating for 15 min at 37°C with shaking at 125 rpm. Proteins were then analyzed via capture ELISA as above, with samples captured on streptavidin-coated plates and probed with S-specific antibodies.

Negative-stain transmission electron microscopy

Purified spike protein was diluted to ~10 μ g/ml in PBS and applied to glow-discharged carbon films supported by formvar on 400-mesh copper grids (ProSciTech). Samples were applied for 2 min before washing three times with water. The grids were then stained with 1% uranyl acetate and air-dried before imaging on a Hitachi HT7700 transmission electron microscope at 120-kV and $\times$ 30,000 magnification.

HD-MAP coating and application

HD-MAPs were provided by Vaxxas Pty Ltd. (Brisbane, Australia). The patches are produced by injection molding medical-grade synthetic polymer to produce microprojection arrays of 5000 projections/cm², with each projection 250 μ m in length with a tip diameter of 25 μ m. Before vaccine coating, HD-MAPs were cleaned via oxygen plasma treatment for 5 min at 30-W power at the Australian National Fabrication Facility, Queensland Node. A vaccine-coating solution consisting of various amounts of SARS-CoV-2 HexaPro spike protein, 0.25% HSA, 0.75% methylcellulose, and varying amounts of the adjuvant QS21 (Desert King) was then applied to the patch. The solution was then dried using a sterile-filtered nitrogen gas stream as previously described (56). Vaccine-coated HD-MAPs were then applied to the flank of mice using those whose hair had previously been removed at the vaccination site via shaving and depilatory cream. The HD-MAPs were applied at a velocity of 18 to 20 m/s using a custom applicator.

SEM of HD-MAPs

HD-MAPs were coated with 15 nm of platinum and imaged by SEM using a Hitachi SU3500 at the Centre for Microscopy and Microanalysis at the University of Queensland. Samples were at a 45° angle.

Immunization of BALB/c mice

Naïve 6- to 8-week-old female BALB/c mice were randomly divided into six groups of eight mice and vaccinated either via HD-MAP application or intradermal injection with 2 μ g of SARS-CoV-2 S HexaPro, 2 μ g of SARS-CoV-2 S HexaPro with the adjuvant QS21 (Desert King), or vehicle only control. All mice were immunized twice at 21-day intervals. Blood was taken before each immunization and 21 days after the final immunization via tail bleed or cardiac puncture. A BAL was also performed at the time of cardiac puncture. The blood was allowed to clot overnight at 4°C before the serum was harvested by centrifugation at 10,000g for 10 min at 4°C. Samples were stored at -20°C until further analysis. The BAL fluid was centrifuged at 1000g for 5 min to remove debris and the supernatant was harvested and stored at -80°C until further analysis.

ELISpot

Spleens from mice were collected and processed into single-cell suspensions in RPMI1640 media supplemented with 10% heat-inactivated

fetal calf serum and penicillin/streptomycin (R10 media). Red blood cells were lysed using eBioscience RBC lysis buffer (Thermo Fisher Scientific) and resuspended in R10 media to stop the lysis. Splenocytes were counted and 100,000 cells per well were added to the plates of the Mouse IFN- γ ELISpot^{PLUS} (HRP) kit (Mabtech). Cells were then stimulated for 18 hours at 37°C with SARS-CoV-2 S PepTivator peptides (Miltenyi Biotec) or media alone as a negative control. Spots were developed as per the manufacturer's instructions. Spots were quantified by eye and plotted as SFU per million cells.

K18-hACE2 mouse challenge model

Female K18-hACE2 mice (6 to 8 weeks old) were immunized via HD-MAP application as before or left unimmunized as naïve controls. Mice received one or two immunizations, 21 days apart, and were challenged with 1×10^4 PFU of SARS-CoV-2 (VIC01 isolate) 21 days after the final immunization via intranasal inoculation (20 μ l total volume) while under isoflurane anesthesia. Blood was taken before each immunization and before challenge. Mice were monitored daily for weight loss and disease severity and culled when weight loss surpassed 15% of prechallenge body weight. After culling, lung and brain tissue were harvested for viral titer assessment immunoplaque assay. A lung lobe and brain hemisphere from each animal was fixed in 10% neutral buffered formalin and processed for paraffin embedding, and hematoxylin-eosin-stained sections were examined by a veterinary pathologist blinded to the treatments.

Serum ELISAs

Serum from mouse immunizations was assessed for SARS-CoV-2 S-specific IgG levels via ELISA as previously described (7). Briefly, SARS-CoV-2 spike protein was coated onto ELISA plates at 2 μ g/ml in PBS overnight at 4°C. Plates were blocked and serial dilutions of serum were added to the plates for 1 hour at 37°C. Serum binding was detected using an HRP-linked goat anti-mouse secondary antibody and TMB substrate as discussed previously.

Plaque reduction neutralization tests

Serum and BAL fluid were assessed for SARS-CoV-2 neutralization activity via PRNT as previously described (70). Briefly, heat-inactivated serum or BAL fluid was serially diluted in DMEM supplemented with 2% fetal bovine serum and penicillin/streptomycin (Gibco) before virus was added. Samples were incubated for 30 min at 37°C before being added to confluent VeroE6 monolayers in 96-well plates. Infection was allowed to proceed for 1 hour at 37°C before virus inoculum was removed and overlay medium was added. Cells were fixed with 80% acetone 14 to 16 hours after infection and allowed to dry before plaque visualization with SARS-CoV-2 spike-specific mAbs CR3022 or S309 and IRDye 800CW-conjugated goat anti-human secondary antibodies. Plates were scanned using an Odyssey CLx imaging system (LI-COR).

Assessment of viral titer in mouse organs

Viral titer in the lungs of mice was determined via immunoplaque assay as previously described (70). Briefly, lung and brain tissues were homogenized on a Bead Ruptor 24 Elite (Omni International, Kennesaw, GA) and centrifuged at 12,000g for 7.5 min at 4°C before performing serial dilutions, which were added to VeroE6 cells in 96-well tissue culture plates. Plates were fixed and plaques were visualized via immunostaining.

Statistical analysis

GraphPad Prism 9 software was used for statistical analysis and generation of graphs and figures. Data are presented as mean with SD or SEM, as described in the figure legends. Statistical significance was determined via one-way analysis of variance (ANOVA) with Tukey's multiple comparison test, with $P < 0.05$ considered statistically significant.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <https://science.org/doi/10.1126/sciadv.abj8065>

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

- P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Liu, Y. Chen, X.-R. Shen, X. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.-F. Xiao, Z.-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273 (2020).
- K. S. Corbett, B. Flynn, K. E. Foulds, J. R. Francica, S. Boyoglu-Barnum, A. P. Werner, B. Flach, S. O'Connell, K. W. Bock, M. Minai, B. M. Nagata, H. Andersen, D. R. Martinez, A. T. Noe, N. Douek, M. M. Donaldson, N. N. Nji, G. S. Alvarado, D. K. Edwards, D. R. Flebbe, E. Lamb, N. A. Doria-Rose, B. C. Lin, M. K. Louder, S. O'Dell, S. D. Schmidt, E. Phung, L. A. Chang, C. Yap, J.-P. M. Todd, L. Pessaint, A. Van Ry, S. Browne, J. Greenhouse, T. Putman-Taylor, A. Strasbaugh, T.-A. Campbell, A. Cook, A. Dodson, K. Steingrebe, W. Shi, Y. Zhang, O. M. Abiona, L. Wang, A. Pegu, E. S. Yang, K. Leung, T. Zhou, I.-T. Teng, A. Widge, I. Gordon, L. Novik, R. A. Gillespie, R. J. Loomis, J. I. Molina, G. Stewart-Jones, S. Himansu, W.-P. Kong, M. C. Nason, K. M. Morabito, T. J. Ruckwardt, J. E. Ledgerwood, M. R. Gaudinski, P. D. Kwong, J. R. Mascola, A. Carfi, M. G. Lewis, R. S. Baric, A. M. Dermott, I. N. Moore, N. J. Sullivan, M. Roederer, R. A. Seder, B. S. Graham, Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *N. Engl. J. Med.* **383**, 1544–1555 (2020).
- K. S. Corbett, D. K. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-Barnum, R. A. Gillespie, S. Himansu, A. Schäfer, C. T. Ziawo, A. T. Di Piazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch, D. R. Martinez, K. W. Bock, M. Minai, B. M. Nagata, G. B. Hutchinson, K. Wu, C. Henry, K. Bahl, D. Garcia-Dominguez, L. Z. Ma, I. Renzi, W.-P. Kong, S. D. Schmidt, L. N. Moore, K. M. Morabito, J. R. Mascola, R. S. Baric, A. Carfi, N. E. Altaras, E. Narayanan, M. Metkar, V. Presnyak, C. Liu, M. K. Louder, W. Shi, K. Leung, E. S. Yang, A. West, K. L. Gully, L. J. Stevens, N. Wang, D. Wrapp, N. A. Doria-Rose, G. Stewart-Jones, H. Bennett, G. S. Alvarado, M. C. Nason, T. J. Ruckwardt, J. S. McLellan, M. R. Denison, J. D. Chappell, I. N. Moore, K. M. Morabito, J. R. Mascola, R. S. Baric, A. Carfi, B. S. Graham, SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature* **586**, 567–571 (2020).
- E. E. Walsh, R. W. Frenck Jr., A. R. Falsey, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, K. Neuzil, M. J. Mulligan, R. Bailey, K. A. Swanson, P. Li, K. Koury, W. Kalina, D. Cooper, C. Fontes-Garfias, P.-Y. Shi, Ö. Türeci, K. R. Tompkins, K. E. Lyke, V. Raabe, P. R. Dormitzer, K. U. Jansen, U. Şahin, W. C. Gruber, Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. *N. Engl. J. Med.* **383**, 2439–2450 (2020).
- T. R. F. Smith, A. Patel, S. Ramos, D. Elwood, X. Zhu, J. Yan, E. N. Gary, S. N. Walker, K. Schultheis, M. Purwar, Z. Xu, J. Walters, P. Bhojnagarwala, M. Yang, N. Chokkalingam, P. Pezzoli, E. Parzych, E. L. Reuschel, A. Doan, N. Tursi, M. Vasquez, J. Choi, E. Tello-Ruiz, I. Maricic, M. A. Bah, Y. Wu, D. Amante, D. H. Park, Y. Dia, A. R. Ali, F. I. Zaidi, A. Generotti, K. Y. Kim, T. A. Herring, S. Reeder, V. M. Andrade, K. Buttigieg, G. Zhao, J.-M. Wu, D. Li, L. Bao, J. Liu, W. Deng, C. Qin, A. S. Brown, M. Khoshnejad, N. Wang, J. Chu, D. Wrapp, J. S. McLellan, K. Muthumani, B. Wang, M. W. Carroll, J. Joseph Kim, J. Boyer, D. W. Kulp, L. M. P. F. Humeau, D. B. Weiner, K. E. Broderick, Immunogenicity of a DNA vaccine candidate for COVID-19. *Nat. Commun.* **11**, 2601 (2020).
- J.-H. Tian, N. Patel, R. Haupt, H. Zhou, S. Weston, H. Hammond, J. Logue, A. D. Portnoff, J. Norton, M. Guebre-Xabier, B. Zhou, K. Jacobson, S. Maciejewski, R. Khatoon, M. Wisniewska, W. Moffitt, S. Kluepfel-Stahl, B. Ekechukwu, J. Papin, S. Boddapati, C. Jason Wong, P. A. Piedra, M. B. Frieman, M. J. Massare, L. Fries, K. L. Bengtsson, L. Stertman, L. Ellingsworth, G. Glenn, G. Smith, SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. *Nat. Commun.* **12**, 372 (2021).
- D. Watterson, D. K. Wijesundara, N. Modhiran, F. L. Mordant, Z. Li, M. S. Avumegah, C. L. D. McMillan, J. Lackenby, K. Guilfoyle, G. van Amerongen, K. Stittelaar, S. T. Cheung, S. Bibby, M. Daleris, K. Hoger, M. Gillard, E. Radunz, M. L. Jones, K. Hughes, B. Hughes, J. Goh, D. Edwards, J. Scoble, L. Pearce, L. Kowalczyk, T. Phan, M. La, L. Lu, T. Pham, Q. Zhou, D. A. Brockman, S. J. Morgan, C. Lau, M. H. Tran, P. Tapley, F. Villalón-Letelier, J. Barnes, A. Young, N. Jaberolansari, C. A. Scott, A. Isaacs, A. A. Amarilla, A. A. Khromykh, J. Ma van den Brand, P. C. Reading, C. Ranasinghe, K. Subbarao, T. P. Munro, P. R. Young, K. J. Chappell, Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. *Clin. Transl. Immunol.* **10**, e1269 (2021).
- N. van Doremalen, T. Lambe, A. Spencer, S. Belij-Rammerstorfer, J. N. Purushotham, J. R. Port, V. A. Avanzato, T. Bushmaker, A. Flaxman, M. Ulaszewska, F. Feldmann, E. R. Allen, H. Sharpe, J. Schulz, M. Holbrook, A. Okumura, K. Meade-White, L. Pérez-Pérez, N. J. Edwards, D. Wright, C. Bissett, C. Gilbride, B. N. Williamson, R. Rosenke, D. Long, A. Ishwarbhai, R. Kailath, L. Rose, S. Morris, C. Powers, J. Lovaglio, P. W. Hanley, D. Scott, G. Saturday, E. de Wit, S. C. Gilbert, V. J. Munster, ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. *Nature* **586**, 578–582 (2020).
- D. Y. Logunov, I. V. Dolzhikova, O. V. Zubkova, A. I. Tukhvatulin, D. V. Shcheblyakov, A. S. Dzharullaeva, D. M. Grousova, A. S. Erokhova, A. V. Kovyrshina, A. G. Botikov, F. M. Izhaeva, O. Popova, T. A. Ozharovskaya, I. B. Esmagambetov, I. A. Favorskaya, D. I. Zrelkin, D. V. Voronina, D. N. Shcherbinin, A. S. Semikhin, Y. V. Simakova, E. A. Tokarskaya, N. L. Lubenets, D. A. Egorova, M. M. Shmarov, N. A. Nikitenko, L. F. Morozova, E. A. Smolyarchuk, E. V. Kryukov, V. F. Babira, S. V. Borisevich, B. S. Noradsky, P. A. L. Gintsburg, Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. *Lancet* **396**, 887–897 (2020).
- F.-C. Zhu, Y.-H. Li, X.-H. Guan, L.-H. Hou, W.-J. Wang, J.-X. Li, S.-P. Wu, B.-S. Wang, Z. Wang, L. Wang, S.-Y. Jia, H.-D. Jiang, L. Wang, T. Jiang, Y. Hu, J.-B. Gou, S.-B. Xu, J.-J. Xu, X.-W. Wang, W. Wang, W. Chen, Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet* **395**, 1845–1854 (2020).
- L. Sanchez-Felipe, T. Vercruyse, S. Sharma, J. Ma, V. Lemmens, D. Loooveren, M. P. A. Javarappa, R. Boudewijns, B. Malengier-Devies, L. Liesenborghs, S. J. F. Kaptein, C. De Keyser, L. Bervoets, S. Debaveye, M. Rasulovala, L. Seldeslachts, L.-H. Li, S. Jansen, M. B. Yakass, B. E. Verstrepen, K. P. Böszörményi, G. Kiemenyi-Kayere, N. van Driel, O. Quay, X. Zhang, S. ter Horst, N. Mishra, W. Dehoutte, J. Matthijnsens, L. Coelmont, C. Vandermeulen, E. Heylen, V. Vergote, D. Schols, Z. Wang, W. Bogers, T. Kuiken, E. Verschoor, C. Cawthorne, K. Van Laere, G. Opdenakker, G. V. Velde, B. Weynand, D. E. Teuwen, P. Matthyis, J. Neyts, H. J. Thibaut, K. Dallmeier, A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. *Nature* **590**, 320–325 (2021).
- T. K. Tan, P. Rijal, R. Rahikainen, A. H. Keeble, L. Schimanski, S. Hussain, R. Harvey, J. W. P. Hayes, J. C. Edwards, R. K. McLean, V. Martini, M. Pedrera, N. Thakur, C. Conceicao, I. Dietrich, H. Shelton, A. Ludi, G. Wilsden, C. Browning, A. K. Zagorajek, D. Bialy, S. Bhat, P. Stevenson-Leggett, P. Hollinghurst, M. Tully, K. Moffat, C. Chiu, R. Waters, A. Gray, M. Azhar, V. Mioulet, J. Newman, A. S. Asfor, A. Burman, S. Crossley, J. A. Hammond, E. Tchilian, B. Charleston, D. Bailey, T. J. Tuthill, S. P. Graham, H. M. E. Duyvesteyn, T. Malinauskas, J. Huo, J. A. Tree, K. R. Buttigieg, R. J. Owens, M. W. Carroll, R. S. Daniels, J. W. McCauley, D. I. Stuart, K.-Y. A. Huang, M. Howarth, A. R. Townsend, A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. *Nat. Commun.* **12**, 542 (2021).
- Q. Gao, L. Bao, H. Mao, L. Wang, K. Xu, M. Yang, Y. Li, L. Zhu, N. Wang, Z. Lv, H. Gao, X. Ge, B. Kan, Y. Hu, J. Liu, F. Cai, D. Jiang, Y. Yin, C. Qin, J. Li, X. Gong, X. Lou, W. Shi, D. Wu, H. Zhang, L. Wang, W. Deng, Y. Li, J. Lu, C. Li, X. Wang, W. Yin, Y. Zhang, C. Qin, Development of an inactivated vaccine candidate for SARS-CoV-2. *Science* **369**, 77–81 (2020).
- H. Wang, Y. Zhang, B. Huang, W. Deng, Y. Quan, W. Wang, W. Xu, Y. Zhao, N. Li, J. Zhang, H. Liang, L. Bao, Y. Xu, L. Ding, W. Zhou, H. Gao, J. Liu, P. Niu, L. Zhao, W. Zhen, H. Fu, S. Yu, Z. Zhang, G. Xu, C. Li, Z. Lou, M. Xu, C. Qin, G. Wu, G. F. Gao, W. Tan, X. Yang, Development of an inactivated vaccine candidate, BBIBP-CoV, with potent protection against SARS-CoV-2. *Cell* **182**, 713–721.e9 (2020).
- R. E. Chen, X. Zhang, J. B. Case, E. S. Winkler, Y. Liu, L. A. Van Blargan, J. Liu, J. M. Errico, X. Xie, N. Suryadevara, P. Gilchuk, S. J. Zost, S. Tahan, L. Droit, J. S. Turner, W. Kim, A. J. Schmitz, M. Thapa, D. Wang, A. C. M. Boon, R. M. Presti, J. A. O'Halloran, A. H. J. Kim, P. Deepak, D. Pinto, D. H. Fremont, J. E. Crowe Jr., D. Corti, H. W. Virgin, A. H. Ellebedy, P.-Y. Shi, M. S. Diamond, Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nat. Med.* **27**, 717–726 (2021).
- X. Xie, Y. Liu, J. Liu, X. Zhang, J. Zou, C. R. Fontes-Garfias, H. Xia, K. A. Swanson, M. Cutler, D. Cooper, V. D. Menachery, S. C. Weaver, P. R. Dormitzer, P.-Y. Shi, Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat. Med.* **27**, 620–621 (2021).
- D. Planas, T. Bruel, L. Grzelak, F. Guivel-Benhassine, I. Staropoli, F. Porrot, C. Planchais, J. Buchrieser, M. M. Rajah, E. Bishop, M. Albert, F. Donati, M. Prot, S. Behillil, V. Enouf, M. Maquart, M. Smati-Lafarge, E. Varon, F. Schortgen, L. Yahyaoui, M. Gonzalez, J. De Sèze, H. Péré, D. Veyer, A. Sève, E. Simon-Lorière, S. Fafi-Kremer, K. Stefic, H. Mouquet, L. Hocqueloux, S. van der Werf, T. Praczuk, O. Schwartz, Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nature Medicine* **27**, 917–924 (2021).
- S. Cele, I. Gazy, L. Jackson, S.-H. Hwa, H. Tegally, G. Lustig, J. Giandhari, S. Pillay, E. Wilkinson, Y. Naidoo, F. Karim, Y. Ganga, K. Khan, M. Bernstein, A. B. Balazs, B. I. Gossnell, W. Hanekom, M.-Y. S. Moosa; Network for Genomic Surveillance in South Africa;

- COMMIT-KZN Team, R. J. Lessells, T. de Oliveira, A. Sigal, Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. *Nature* **593**, 142–146 (2021).
19. D. J. A. Crommelin, T. J. Anchordoquy, D. B. Volkin, W. Jiskoot, E. Mastrobattista, Addressing the cold reality of mRNA vaccine stability. *J. Pharm. Sci.* **110**, 997–1001 (2021).
 20. A. H. Forster, K. Witham, A. C. I. Depelsenaire, M. Veitch, J. W. Wells, A. Wheatley, M. Pryor, J. D. Lickliter, B. Francis, S. Rockman, J. Bodle, P. Treasure, J. Hickling, G. J. P. Fernando, Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. *PLOS Med.* **17**, e1003024 (2020).
 21. S. Babiuk, M. Baca-Estrada, L. A. Babiuk, C. Ewen, M. Foldvari, Cutaneous vaccination: The skin as an immunologically active tissue and the challenge of antigen delivery. *J. Control. Release* **66**, 199–214 (2000).
 22. H.-I. Ng, Z. K. Tuong, G. J. P. Fernando, A. C. I. Depelsenaire, S. C. Meliga, I. H. Frazer, M. A. F. Kendall, Microprojection arrays applied to skin generate mechanical stress, induce an inflammatory transcriptome and cell death, and improve vaccine-induced immune responses. *npj Vaccines* **4**, 41 (2019).
 23. D. A. Muller, J. Henricson, S. B. Baker, T. Togö, C. M. Jayashi Flores, P. A. Lemaire, A. Forster, C. D. Anderson, Innate local response and tissue recovery following application of high density microarray patches to human skin. *Sci. Rep.* **10**, 18468 (2020).
 24. F. E. Pearson, C. L. McNeilly, M. L. Crichton, C. A. Primiero, S. R. Yukiko, G. J. P. Fernando, X. Chen, S. C. Gilbert, A. V. S. Hill, M. A. F. Kendall, Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. *PLOS ONE* **8**, e67888 (2013).
 25. G. J. P. Fernando, J. Hickling, C. M. Jayashi Flores, P. Griffin, C. D. Anderson, S. Rachel Skinner, C. Davies, K. Witham, M. Pryor, J. Bodle, S. Rockman, I. H. Frazer, A. H. Forster, Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). *Vaccine* **36**, 3779–3788 (2018).
 26. T. W. Prow, X. Chen, N. A. Prow, G. J. P. Fernando, C. S. E. Tan, A. P. Raphael, D. Chang, M. P. Ruutu, D. W. K. Jenkins, A. Pyke, M. L. Crichton, K. Raphaelli, L. Y. H. Goh, I. H. Frazer, M. S. Roberts, J. Gardner, A. A. Khromykh, A. Suhrbier, R. A. Hall, M. A. F. Kendall, Nanopatch-targeted skin vaccination against West Nile virus and Chikungunya virus in mice. *Small* **6**, 1776–1784 (2010).
 27. F. E. Pearson, D. A. Muller, L. Roalfe, M. Zancolli, D. Goldblatt, M. A. F. Kendall, Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch. *Vaccine* **33**, 6675–6683 (2015).
 28. D. A. Muller, F. E. Pearson, G. J. P. Fernando, C. Agyei-Yeboah, N. S. Owens, S. R. Corrie, M. L. Crichton, J. C. J. Wei, W. C. Weldon, M. Steven Oberste, P. R. Young, M. A. F. Kendall, Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. *Sci. Rep.* **6**, 22094 (2016).
 29. D. A. Muller, G. J. P. Fernando, N. S. Owens, C. Agyei-Yeboah, J. C. J. Wei, A. C. I. Depelsenaire, A. Forster, P. Fahey, W. C. Weldon, M. Steven Oberste, P. R. Young, M. A. F. Kendall, High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. *Sci. Rep.* **7**, 12644 (2017).
 30. D. A. Muller, A. C. I. Depelsenaire, A. E. Shannon, D. Watterson, S. R. Corrie, N. S. Owens, C. Agyei-Yeboah, S. T. M. Cheung, J. Zhang, G. J. P. Fernando, M. A. F. Kendall, P. R. Young, Efficient delivery of dengue virus subunit vaccines to the skin by microprojection arrays. *Vaccines (Basel)* **7**, 189 (2019).
 31. G. J. P. Fernando, X. Chen, T. W. Prow, M. L. Crichton, E. J. Fairmaid, M. S. Roberts, I. H. Frazer, L. E. Brown, M. A. F. Kendall, Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. *PLOS ONE* **5**, e10266 (2010).
 32. G. J. P. Fernando, X. Chen, C. A. Primiero, S. R. Yukiko, E. J. Fairmaid, H. J. Corbett, I. H. Frazer, L. E. Brown, M. A. F. Kendall, Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. *J. Control. Release* **159**, 215–221 (2012).
 33. H. J. Corbett, G. J. P. Fernando, X. Chen, I. H. Frazer, M. A. F. Kendall, Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. *PLOS ONE* **5**, e13460 (2010).
 34. J. Arya, M. R. Prausnitz, Microneedle patches for vaccination in developing countries. *J. Control. Release* **240**, 135–141 (2016).
 35. S. Marshall, L. J. Sahn, A. C. Moore, The success of microneedle-mediated vaccine delivery into skin. *Hum. Vaccin. Immunother.* **12**, 2975–2983 (2016).
 36. C.-L. Hsieh, J. A. Goldsmith, J. M. Schaub, A. M. Di Venere, H.-C. Kuo, K. Javanmardi, K. C. Le, D. Wrapp, A. G. Lee, Y. Liu, C.-W. Chou, P. O. Byrne, C. K. Hjorth, N. V. Johnson, J. Ludes-Meyers, A. W. Nguyen, J. Park, N. Wang, D. Amengor, J. J. Lavinder, G. C. Ippolito, J. A. Maynard, I. J. Finkelstein, J. S. McLellan, Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science* **369**, 1501–1505 (2020).
 37. D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. Alejandra Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Camerini, J. B. Case, R. E. Chen, C. Havenar-Daughton, G. Snell, A. Telenti, H. W. Virgin, A. Lanzavecchia, M. S. Diamond, K. Fink, D. Velesler, D. Corti, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **583**, 290–295 (2020).
 38. H.-X. Sun, Y. Xie, Y.-P. Ye, Advances in saponin-based adjuvants. *Vaccine* **27**, 1787–1796 (2009).
 39. M. L. Crichton, A. Ansaldo, X. Chen, T. W. Prow, G. J. P. Fernando, M. A. F. Kendall, The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. *Biomaterials* **31**, 4562–4572 (2010).
 40. S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. P. Nkolola, A. Schäfer, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, D. R. Martinez, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, A. O. Hassan, N. M. Kafai, E. S. Winkler, J. M. Fox, S. Shrihari, B. K. Mueller, J. Meiler, A. Chandrashekar, N. B. Mercado, J. J. Steinhart, K. Ren, Y.-M. Loo, N. L. Kallewaard, B. T. McCune, S. P. Keeler, M. J. Holtzman, D. H. Barouch, L. E. Gralinski, R. S. Baric, L. B. Thackray, M. S. Diamond, R. H. Carnahan, J. E. Crowe Jr., Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature* **584**, 443–449 (2020).
 41. T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W.-T. He, O. Limbo, C. Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L. Peng, S. Ramirez, J. Ricketts, M. J. Ricciardi, S. A. Rawlings, N. C. Wu, M. Yuan, D. M. Smith, D. Nemazee, J. R. Teijaro, J. E. Voss, I. A. Wilson, R. Andrabi, B. Briney, E. Landais, D. Sok, J. G. Jardine, D. R. Burton, Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science* **369**, 956–963 (2020).
 42. X. Chi, R. Yan, J. Zhang, G. Zhang, Y. Zhang, M. Hao, Z. Zhang, P. Fan, Y. Dong, Y. Yang, Z. Chen, Y. Guo, J. Zhang, Y. Li, X. Song, Y. Chen, L. Xia, L. Fu, L. Hou, J. Xu, C. Yu, J. Li, Q. Zhou, W. Chen, A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science* **369**, 650–655 (2020).
 43. M. W. Russell, Z. Moldoveanu, P. L. Ogra, J. Mestecky, Mucosal immunity in COVID-19: A neglected but critical aspect of SARS-CoV-2 infection. *Front. Immunol.* **11**, 611337 (2020).
 44. M. Prendecki, C. Clarke, J. Brown, A. Cox, S. Gleeson, M. Guckian, P. Randell, A. D. Pria, L. Lightstone, X.-N. Xu, W. Barclay, S. P. McAdoo, P. Kelleher, M. Willicombe, Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. *Lancet* **397**, 1178–1181 (2021).
 45. A. Tarke, J. Sidney, N. Methot, E. Du, Y. Zhang, J. M. Dan, B. Goodwin, P. Rubiro, A. Sutherland, E. Wang, A. Frazier, S. I. Ramirez, S. A. Rawlings, D. M. Smith, R. da Silva Antunes, B. Peters, R. H. Scheuermann, D. Weiskopf, S. Crotty, A. Grifoni, A. Sette, Impact of SARS-CoV-2 variants on the total CD4⁺ and CD8⁺ T cell reactivity in infected or vaccinated individuals. *Cell Rep. Med.* **2**, 100355 (2021).
 46. D. Weiskopf, K. S. Schmitz, M. P. Raadsen, A. Grifoni, N. M. A. Okba, H. Endeman, J. P. C. van den Akker, R. Molenkamp, M. P. G. Koopmans, E. C. M. van Gorp, B. L. Haagmans, R. L. de Swart, A. Sette, R. D. de Vries, Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. *Science Immunology* **5**, eabd2071 (2020).
 47. L. Yurkovetskiy, X. Wang, K. E. Pascal, C. Tomkins-Tinch, T. P. Nyalile, Y. Wang, A. Baum, W. E. Diehl, A. Dauphin, C. Carbone, K. Veinotte, S. B. Egri, S. F. Schaffner, J. E. Lemieux, J. B. Munro, A. Rafique, A. Barve, P. C. Sabeti, C. A. Kyrtatos, N. V. Dudkina, K. Shen, J. Luban, Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. *Cell* **183**, 739–751.e8 (2020).
 48. D. Zhou, W. Dejnirattisai, P. Supasa, C. Liu, A. J. Mentzer, H. M. Ginn, Y. Zhao, H. M. E. Duyvesteyn, A. Tuekprakhon, R. Nutalai, B. Wang, G. C. Paesen, C. Lopez-Camacho, J. Slon-Campos, B. Hallis, N. Coombes, K. Bewley, S. Charlton, T. S. Walter, D. Skelly, S. F. Lumley, C. Dold, R. Levin, T. Dong, A. J. Pollard, J. C. Knight, D. Crook, T. Lambe, E. Clutterbuck, S. Bibi, A. Flaxman, M. Bittaye, S. Belij-Rammerstorfer, S. Gilbert, W. James, M. W. Carroll, P. Klenerman, E. Barnes, S. J. Dunachie, E. E. Fry, J. Mongkolsapaya, J. Ren, D. I. Stuart, G. R. Screaton, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* **184**, 2348–2361.e6 (2021).
 49. E. S. Winkler, A. L. Bailey, N. M. Kafai, S. Nair, B. T. McCune, J. Yu, J. M. Fox, R. E. Chen, J. T. Earnest, S. P. Keeler, J. H. Ritter, L.-I. Kang, S. Dort, A. Robichaud, R. Head, M. J. Holtzman, M. S. Diamond, SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. *Nat. Immunol.* **21**, 1327–1335 (2020).
 50. L. Caly, J. Druce, J. Roberts, K. Bond, T. Tran, R. Kostecki, Y. Yoga, W. Naughton, G. Taiaroa, T. Seemann, M. B. Schultz, B. P. Howden, T. M. Korman, S. R. Lewin, D. A. Williamson, M. G. Catton, Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. *Med. J. Aust.* **212**, 459–462 (2020).
 51. E. Song, C. Zhang, B. Israelow, A. Lu-Culligan, A. V. Prado, S. Skriabine, P. Lu, O.-E. Weizman, F. Liu, Y. Dai, K. Szigeti-Buck, Y. Yasumoto, G. Wang, C. Castaldi, J. Heltke, E. Ng, J. Wheeler, M. M. Alfajaro, E. Levavasseur, B. Fontes, N. G. Ravindra, D. Van Dijk, S. Mane, M. Gunel, A. Ring, S. A. Jaffar Kazmi, K. Zhang, C. B. Wilen, T. L. Horvath, I. Plu, S. Haik, J.-L. Thomas, A. Louvi, S. F. Farhadian, A. Huttner, D. Seilhean, N. Renier, K. Bilguvar, A. Iwasaki,

- Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J. Exp. Med.* **218**, e20202135 (2021).
52. A. C. I. Depelseinaire, S. C. Meliga, C. L. McNeilly, F. E. Pearson, J. W. Coffey, O. L. Haigh, C. J. Flaim, I. H. Frazer, M. A. F. Kendall, Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity. *J. Invest. Dermatol.* **134**, 2361–2370 (2014).
 53. R. J. Edwards, K. Mansouri, V. Stalls, K. Manne, B. Watts, R. Parks, K. Janowska, S. M. C. Gobeil, M. Kopp, D. Li, X. Lu, Z. Mu, M. Deyton, T. H. Oguin III, J. Sprent, W. Williams, K. O. Saunders, D. Montefiori, D. D. Sempowski, R. Henderson, S. Munir Alam, B. F. Haynes, P. Acharya, Cold sensitivity of the SARS-CoV-2 spike ectodomain. *Nat. Struct. Mol. Biol.* **28**, 128–131 (2021).
 54. M. Teresa Aguado, J. Barratt, J. R. Beard, B. B. Blomberg, W. H. Chen, J. Hickling, T. B. Hyde, M. Jit, R. Jones, G. A. Poland, M. Friede, J. R. Ortiz, Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22–23 March 2017. *Vaccine* **36**, 921–931 (2018).
 55. Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members, Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. *Lancet* **397**, 562–564 (2021).
 56. J. J. Y. Choo, L. J. Vet, C. L. D. McMillan, J. J. Harrison, C. A. P. Scott, A. C. I. Depelseinaire, G. J. P. Fernando, D. Watterson, R. A. Hall, P. R. Young, J. Hobson-Peters, D. A. Muller, A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice. *npj Vaccines* **6**, 66 (2021).
 57. C. Rydzynski, M. Moderbacher, S. I. Ramirez, J. M. Dan, A. Grifoni, K. M. Hastie, D. Weiskopf, S. Belanger, R. K. Abbott, C. Kim, J. Choi, Y. Kato, E. G. Crotty, C. Kim, S. A. Rawlings, J. Mateus, L. P. V. Tse, A. Frazier, R. Baric, B. Peters, J. Greenbaum, E. O. Saphire, D. M. Smith, A. Sette, S. Crotty, Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. *Cell* **183**, 996–1012.e19 (2020).
 58. E. Kim, G. Erdos, S. Huang, T. W. Kenniston, S. C. Balmert, C. D. Carey, V. Stalin Raj, M. W. Epperly, W. B. Klimstra, B. L. Haagmans, E. Korkmaz, L. D. Falo Jr., A. Gambotto, Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. *EBioMedicine* **55**, 102743 (2020).
 59. C. Kuwentrai, J. Yu, L. Rong, B.-Z. Zhang, Y.-F. Hu, H.-R. Gong, Y. Dou, J. Deng, J.-D. Huang, C. Xu, Intradermal delivery of receptor-binding domain of SARS-CoV-2 spike protein with dissolvable microneedles to induce humoral and cellular responses in mice. *Bioeng. Transl. Med.* **6**, e10202 (2020).
 60. L. Zanin, G. Saraceno, P. P. Panciani, G. Renisi, L. Signorini, K. Migliorati, M. M. Fontanella, SARS-CoV-2 can induce brain and spine demyelinating lesions. *Acta Neurochir.* **162**, 1491–1494 (2020).
 61. T. Moriguchi, N. Harii, J. Goto, D. Harada, H. Sugawara, J. Takamino, M. Ueno, H. Sakata, K. Kondo, N. Myose, A. Nakao, M. Takeda, H. Haro, O. Inoue, K. Suzuki-Inoue, K. Kubokawa, S. Ogihara, T. Sasaki, H. Kinouchi, H. Kojin, M. Ito, H. Onishi, T. Shimizu, Y. Sasaki, N. Enomoto, H. Ishihara, S. Furuya, T. Yamamoto, S. Shimada, A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int. J. Infect. Dis.* **94**, 55–58 (2020).
 62. L. R. Baden, H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemer, S. A. Spector, N. Rouphael, C. Buddy Creech, J. M. Gittigan, S. Khetan, N. Segall, J. Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B. S. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, T. Zaks; for the COVE Study Group, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N. Engl. J. Med.* **384**, 403–416 (2021).
 63. C. Keech, G. Albert, I. Cho, A. Robertson, P. Reed, S. Neal, J. S. Plested, M. Zhu, S. Cloney-Clark, H. Zhou, G. Smith, N. Patel, M. B. Frieman, R. E. Haupt, J. Logue, M. M. Grath, S. Weston, P. A. Piedra, C. Desai, K. Callahan, M. Lewis, P. Price-Abbott, N. Formica, V. Shinde, L. Fries, J. D. Lickliter, P. Griffin, B. Wilkinson, G. M. Glenn, Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *N. Engl. J. Med.* **383**, 2320–2332 (2020).
 64. F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G. P. Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck Jr., L. L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Şahin, K. U. Jansen, W. C. Gruber; for the C4591001 Clinical Trial Group, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).
 65. M. Voysey, S. A. Costa Clemens, S. A. Madhi, L. Y. Weckx, P. M. Folegatti, P. K. Aley, B. Angus, V. L. Baillie, S. L. Barnabas, Q. E. Bhorat, S. Bibi, C. Briner, P. Cicconi, A. M. Collins, R. Colin-Jones, C. L. Cutland, T. C. Darton, K. Dheda, C. J. A. Duncan, K. R. W. Emary, K. J. Ewer, L. Fairlie, S. N. Faust, S. Feng, D. M. Ferreira, A. Finn, A. L. Goodman, C. M. Green, C. A. Green, P. T. Heath, C. Hill, H. Hill, I. Hirsch, S. H. C. Hodgson, A. Izu, S. Jackson, D. Jenkin, C. C. D. Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A. M. Lawrie, A. Lelliott, V. Libri, P. J. Lillie, R. Mallory, A. V. A. Mendes, E. P. Milan, A. M. Minassian, A. M. Gregor, H. Morrison, Y. F. Mujadidi, A. Nana, P. J. O'Reilly, S. D. Padayachee, A. Pittella, E. Plested, K. M. Pollock, M. N. Ramasamy, S. Rhead, A. V. Schwarzbald, N. Singh, A. Smith, R. Song, M. D. Snape, E. Sprinz, R. K. Sutherland, R. Tarrant, E. C. Thomson, M. Estée Török, M. Toshner, D. P. J. Turner, J. Vekemans, T. L. Villafana, M. E. E. Watson, C. J. Williams, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert, A. J. Pollard; Oxford COVID Vaccine Trial Group, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* **397**, 99–111 (2021).
 66. J. Sadoff, M. L. Gars, G. Shukarev, D. Heerwegh, C. Truysers, A. M. de Groot, J. Stoop, S. Tete, W. Van Damme, I. Leroux-Roels, P.-J. Berghmans, M. Kimmel, P. Van Damme, J. de Hoon, W. Smith, K. E. Stephenson, S. C. De Rosa, K. W. Cohen, M. J. McElrath, E. Cormier, G. Scheper, D. H. Barouch, J. Hendriks, F. Struyf, M. Douoguih, J. Van Hoof, H. Schuitemaker, Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. *N. Engl. J. Med.* **384**, 1824–1835 (2021).
 67. A. O. Hassan, N. M. Kafai, I. P. Dmitriev, J. M. Fox, B. K. Smith, I. B. Harvey, R. E. Chen, E. S. Winkler, A. W. Wessel, J. B. Case, E. Kashentseva, B. T. McCune, A. L. Bailey, H. Zhao, L. A. Van Blargan, Y.-N. Dai, M. Ma, L. J. Adams, S. Shrihari, J. E. Danis, L. E. Gralinski, Y. J. Hou, A. Schäfer, A. S. Kim, S. P. Keeler, D. Weiskopf, R. S. Baric, M. J. Holtzman, D. H. Fremont, D. T. Curiel, M. S. Diamond, A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. *Cell* **183**, 169–184.e13 (2020).
 68. A. Greinacher, T. Thiele, T. E. Warkentin, K. Weisser, P. A. Kyrle, S. Eichinger, Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N. Engl. J. Med.* **384**, 2092–2101 (2021).
 69. M. Gu, J. L. Torres, J. Greenhouse, S. Wallace, Chi-I Chiang, A. M. Jackson, M. Porto, S. Kar, Y. Li, A. B. Ward, Y. Wang, One dose of COVID-19 nanoparticle vaccine RVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization. *bioRxiv*, 2021.04.02.438218 (2021). <https://doi.org/10.1101/2021.04.02.438218>.
 70. A. A. Amarilla, N. Modhiran, Y. X. Setoh, N. Y. G. Peng, J. D. J. Sng, B. Liang, C. L. D. McMillan, M. E. Freney, S. T. M. Cheung, K. J. Chappell, A. A. Khromykh, P. R. Young, D. Watterson, An optimized high-throughput immuno-plaque assay for SARS-CoV-2. *Front. Microbiol.* **12**, 625136 (2021).
 71. M. L. Jones, T. Seldon, M. Smede, A. Linville, D. Y. Chin, R. Barnard, S. M. Mahler, D. Munster, D. Hart, P. P. Gray, T. P. Munro, A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. *J. Immunol. Methods* **354**, 85–90 (2010).

Acknowledgments: We thank the Queensland Health Forensic and Scientific Services, Queensland Department of Health, and the Peter Doherty Institute for Infection and Immunity and Melbourne Health, Victoria, Australia, for providing SARS-CoV-2 isolates. We thank K. Chappell, N. Jaberolansar, and A. Young from the University of Queensland for providing technical advice and reagents for antigen purification. We thank the staff at the University of Queensland Biological Resources facility for providing technical assistance. We acknowledge the facilities, and the scientific and technical assistance, of the Australian Microscopy and Microanalysis Research Facility at the Centre for Microscopy and Microanalysis, the University of Queensland. We also thank the staff at the Protein Expression Facility, the University of Queensland. This work was performed in part at the Queensland Node of the Australian National Fabrication Facility, a facility established under the National Collaborative Research Infrastructure Strategy to provide nano- and micro-fabrication for Australia's researchers. We thank H. McMath for assistance with HD-MAP delivery, BL3 facility, and Vivarium at Griffith University. We would also like to thank A. Taylor from the School of Medical Science, Griffith University, for assistance with animal work in the PC3 facility. HD-MAPS were provided by Vaxxas Pty Ltd. **Funding:** This work was supported by Advance Queensland Industry Research Fellowship 2020001511 (D.A.M.) sponsored by Vaxxas and Technovalia; by MRFF 2001931 (N.A.J.M.); and by the University of Queensland Research Training Scholarship (J.J.Y.C. and A. Ic.), and Medical Research Future Fund grant 2001931 (N.A.J.M.). **Author contributions:** Conceptualization: C.L.D.M., J.J.Y.C., D.A.M., and P.R.Y. Methodology: C.L.D.M., J.J.Y.C., A. Id., A.S., and G.J.P.F. Investigation: C.L.D.M., J.J.Y.C., N.M., A.A.A., A.Id., A.S., A.Ic., S.T.M.C., B.L., H.B.-O., A.A., D.A., G.K., and G.J.P.F. Visualization: C.L.D.M. and M.J.L. Funding acquisition: D.A.M., N.A.J.M., and P.R.Y. Project administration: D.A.M. and P.R.Y. Supervision: D.A.M., A.A.K., D.W., P.R.Y., and N.A.J.M. Writing—original draft: C.L.D.M. and J.J.Y.C. Writing—review and editing: D.A.M., P.R.Y., N.A.J.M., and G.J.P.F. **Competing interests:** G.J.P.F., P.R.Y., and D.A.M. are consultants of the HD-MAP development company Vaxxas Pty Ltd. All other authors declare that they have no competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.

Submitted 3 June 2021

Accepted 8 September 2021

Published 29 October 2021

10.1126/sciadv.abj8065

Citation: C. L. D. McMillan, J. J. Y. Choo, A. Idris, A. Supramaniam, N. Modhiran, A. A. Amarilla, A. Isaacs, S. T. M. Cheung, B. Liang, H. Bielefeldt-Othmann, A. Azuar, D. Acharya, G. Kelly, G. J. P. Fernando, M. J. Landsberg, A. A. Khromykh, D. Watterson, P. R. Young, N. A. J. McMillan, D. A. Muller, Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine. *Sci. Adv.* **7**, eabj8065 (2021).